IN2015DN02829A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN02829A IN2015DN02829A IN2829DEN2015A IN2015DN02829A IN 2015DN02829 A IN2015DN02829 A IN 2015DN02829A IN 2829DEN2015 A IN2829DEN2015 A IN 2829DEN2015A IN 2015DN02829 A IN2015DN02829 A IN 2015DN02829A
- Authority
- IN
- India
- Prior art keywords
- compound
- formula
- effective amount
- therapeutically effective
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011001692 | 2011-10-10 | ||
| PCT/EP2012/069936 WO2013053690A1 (en) | 2011-10-10 | 2012-10-09 | Pde9i with imidazo pyrazinone backbone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN02829A true IN2015DN02829A (pt) | 2015-09-11 |
Family
ID=47019007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2829DEN2015 IN2015DN02829A (pt) | 2011-10-10 | 2012-10-09 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9643970B2 (pt) |
| EP (2) | EP3121178B1 (pt) |
| JP (1) | JP2015531401A (pt) |
| CN (2) | CN106905324B (pt) |
| AU (2) | AU2012323085B2 (pt) |
| BR (1) | BR112015007731B1 (pt) |
| CA (1) | CA2886885C (pt) |
| HK (1) | HK1211023A1 (pt) |
| IL (2) | IL237836A (pt) |
| IN (1) | IN2015DN02829A (pt) |
| MA (1) | MA37958B1 (pt) |
| MX (1) | MX370433B (pt) |
| SG (1) | SG11201502728WA (pt) |
| TN (1) | TN2015000100A1 (pt) |
| WO (1) | WO2013053690A1 (pt) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106905324B (zh) * | 2011-10-10 | 2018-09-25 | H.隆德贝克有限公司 | 具有咪唑并吡嗪酮骨架的pde9抑制剂 |
| LT3105226T (lt) | 2014-02-13 | 2019-11-11 | Incyte Corp | Ciklopropilaminai, kaip lsd1 inhibitoriai |
| US9493442B2 (en) | 2014-02-13 | 2016-11-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| PL3105218T3 (pl) | 2014-02-13 | 2020-03-31 | Incyte Corporation | Cyklopropyloaminy jako inhibitory lsd1 |
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| JO3627B1 (ar) * | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| DK3303339T3 (da) * | 2015-07-07 | 2021-04-12 | H Lundbeck As | Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme |
| TW201717948A (zh) * | 2015-08-10 | 2017-06-01 | Ｈ 朗德貝克公司 | 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療 |
| SG10202001219UA (en) | 2015-08-12 | 2020-03-30 | Incyte Corp | Salts of an lsd1 inhibitor |
| JP6877423B2 (ja) * | 2015-11-09 | 2021-05-26 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | がんの処置において有用なジヒドロイミダゾピラジノン誘導体 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| PE20190377A1 (es) | 2016-04-22 | 2019-03-08 | Incyte Corp | Formulaciones de un inhibidor de lsd 1 |
| CN114903900A (zh) * | 2016-07-06 | 2022-08-16 | 伊马拉公司 | 用于治疗外周疾病的pde9抑制剂 |
| CN109843884B (zh) * | 2016-10-18 | 2022-03-04 | H.隆德贝克有限公司 | 作为pde1抑制剂的咪唑并吡嗪酮、吡唑并嘧啶酮和吡唑并吡啶酮 |
| CA3041595A1 (en) * | 2016-10-28 | 2018-05-03 | H. Lundbeck A/S | Combination treatments comprising administration of imidazopyrazinones |
| EP3532064B1 (en) * | 2016-10-28 | 2020-07-29 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
| WO2018154133A1 (en) * | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors |
| IL270792B2 (en) * | 2017-05-26 | 2024-01-01 | Imara Inc | Methods for the preparation and use of PDE9 inhibitors |
| CN111051308A (zh) | 2017-06-08 | 2020-04-21 | 默沙东公司 | 吡唑并嘧啶pde9抑制剂 |
| EP3713936B1 (en) | 2017-11-23 | 2021-10-20 | Basf Se | Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi |
| JP2021526134A (ja) | 2018-05-25 | 2021-09-30 | イマラ インク． | ６−［（３Ｓ，４Ｓ）−４−メチル−ｌ−（ピリミジン−２−イルメチル）ピロリジン−３−イル］−３−テトラヒドロピラン−４−イル−７Ｈ−イミダゾ［ｌ，５−Ａ］ピラジン−８−オンの一水和物および結晶形態 |
| CN112312908A (zh) * | 2018-06-20 | 2021-02-02 | 詹森药业有限公司 | Oga抑制剂化合物 |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| CN114302724A (zh) * | 2019-04-05 | 2022-04-08 | 伊马拉公司 | 用于治疗镰状细胞病的pde9抑制剂 |
| CN114072151A (zh) * | 2019-05-07 | 2022-02-18 | 伊马拉公司 | 用于治疗地中海贫血的pde9抑制剂 |
| WO2022036111A1 (en) * | 2020-08-13 | 2022-02-17 | Imara Inc. | Methods and compositions for treating sickle cell disease |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU230154B1 (hu) | 1997-11-12 | 2015-09-28 | Bayer Intellectual Property Gmbh | Eljárás 2-es helyzetben fenil-szubszituenst hordozó imidazo-triazinon-származékok előállítására |
| AU2291200A (en) | 1999-01-20 | 2000-08-07 | Arzneimittelwerk Dresden Gmbh | Use of imidazo(1,5-a)-pyrido(3,2-e)-pyrazinones as medicaments |
| HN2002000317A (es) * | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| KR20040053210A (ko) | 2001-11-02 | 2004-06-23 | 화이자 프로덕츠 인크. | Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료 |
| GB2388111A (en) | 2002-05-01 | 2003-11-05 | Bayer Ag | Novel imidazotriazinone compounds |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| CA2543522A1 (en) | 2003-10-31 | 2005-05-12 | Pfizer Products Inc. | Phosphodiesterase 9 inhibition as treatment for obesity-related conditions |
| TW200800213A (en) | 2005-09-02 | 2008-01-01 | Abbott Lab | Novel imidazo based heterocycles |
| TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| WO2008029589A1 (fr) | 2006-09-08 | 2008-03-13 | Tokuyama Corporation | Procédé et matériel servant à produire un nitrure d'un élément du groupe iii |
| EP2103613B1 (en) | 2006-12-13 | 2016-02-17 | ASKA Pharmaceutical Co., Ltd. | Quinoxaline derivative |
| US20100113484A1 (en) | 2006-12-13 | 2010-05-06 | Aska Pharmaceutical Co., Ltd. | Treating agent of uropathy |
| ME00954B (me) | 2007-05-11 | 2012-06-20 | Pfizer | Aminoheterociklični spojevi |
| DE102007032349A1 (de) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| US9260432B2 (en) | 2009-09-02 | 2016-02-16 | Concert Pharmaceuticals, Inc. | Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds |
| JP5855109B2 (ja) | 2010-09-20 | 2016-02-09 | フォーラム・ファーマシューティカルズ・インコーポレイテッドＦｏｒｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | イミダゾトリアジノン化合物 |
| HUE028555T2 (en) | 2011-10-07 | 2016-12-28 | Eisai R&D Man Co Ltd | Pyrazolinquinoline Derivatives as PDE9 Inhibitors |
| CN106905324B (zh) * | 2011-10-10 | 2018-09-25 | H.隆德贝克有限公司 | 具有咪唑并吡嗪酮骨架的pde9抑制剂 |
| EP2807163B1 (en) | 2012-01-26 | 2017-03-22 | H. Lundbeck A/S | Pde9 inhibitors with imidazo triazinone backbone |
| EP2828262A4 (en) | 2012-03-19 | 2015-09-23 | Forum Pharmaceuticals Inc | IMIDAZOTRIAZINONVERBINDUNGEN |
-
2012
- 2012-10-09 CN CN201710247417.1A patent/CN106905324B/zh active Active
- 2012-10-09 JP JP2015535994A patent/JP2015531401A/ja active Pending
- 2012-10-09 BR BR112015007731-5A patent/BR112015007731B1/pt active IP Right Grant
- 2012-10-09 EP EP16185105.0A patent/EP3121178B1/en active Active
- 2012-10-09 SG SG11201502728WA patent/SG11201502728WA/en unknown
- 2012-10-09 IN IN2829DEN2015 patent/IN2015DN02829A/en unknown
- 2012-10-09 CA CA2886885A patent/CA2886885C/en active Active
- 2012-10-09 MA MA37958A patent/MA37958B1/fr unknown
- 2012-10-09 MX MX2015004422A patent/MX370433B/es active IP Right Grant
- 2012-10-09 CN CN201280076285.6A patent/CN104703987B/zh active Active
- 2012-10-09 AU AU2012323085A patent/AU2012323085B2/en active Active
- 2012-10-09 WO PCT/EP2012/069936 patent/WO2013053690A1/en active Application Filing
- 2012-10-09 EP EP12772769.1A patent/EP2906562B1/en active Active
- 2012-10-09 US US14/434,308 patent/US9643970B2/en active Active
-
2015
- 2015-03-16 TN TNP2015000100A patent/TN2015000100A1/fr unknown
- 2015-03-19 IL IL237836A patent/IL237836A/en active IP Right Grant
- 2015-11-27 HK HK15111740.3A patent/HK1211023A1/xx unknown
-
2017
- 2017-03-08 US US15/452,827 patent/US9993477B2/en active Active
- 2017-03-20 AU AU2017201873A patent/AU2017201873C1/en active Active
- 2017-07-12 IL IL253448A patent/IL253448A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9643970B2 (en) | 2017-05-09 |
| EP2906562A1 (en) | 2015-08-19 |
| MA37958A1 (fr) | 2017-11-30 |
| HK1211023A1 (en) | 2016-05-13 |
| CN106905324A (zh) | 2017-06-30 |
| IL253448A0 (en) | 2017-09-28 |
| US20170173018A1 (en) | 2017-06-22 |
| AU2012323085B2 (en) | 2017-03-09 |
| JP2015531401A (ja) | 2015-11-02 |
| AU2017201873C1 (en) | 2018-08-02 |
| MA37958B1 (fr) | 2018-10-31 |
| BR112015007731A2 (pt) | 2017-07-04 |
| EP2906562B1 (en) | 2016-10-05 |
| CN104703987A (zh) | 2015-06-10 |
| MX2015004422A (es) | 2015-10-15 |
| CA2886885C (en) | 2019-07-16 |
| AU2017201873A1 (en) | 2017-04-06 |
| EP3121178A1 (en) | 2017-01-25 |
| CN104703987B (zh) | 2017-05-03 |
| SG11201502728WA (en) | 2015-05-28 |
| IL237836A (en) | 2017-07-31 |
| AU2012323085A1 (en) | 2015-04-02 |
| CN106905324B (zh) | 2018-09-25 |
| CA2886885A1 (en) | 2013-04-18 |
| WO2013053690A1 (en) | 2013-04-18 |
| MX370433B (es) | 2019-12-13 |
| US9993477B2 (en) | 2018-06-12 |
| US20150274736A1 (en) | 2015-10-01 |
| EP3121178B1 (en) | 2018-09-19 |
| TN2015000100A1 (en) | 2016-06-29 |
| AU2017201873B2 (en) | 2018-03-29 |
| BR112015007731B1 (pt) | 2022-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN02829A (pt) | ||
| PH12014501695B1 (en) | Pde9 inhibitors with imidazo triazinone backbone | |
| TN2012000287A1 (en) | 2-arylimidazole derivatives as pde10a enzyme inhibitors | |
| MY152949A (en) | Novel phenylimidazole derivatives as pde10a enzyme inhibitors | |
| JO3089B1 (ar) | مشتقات ايميدازول كمثبطات لانزيمات pde10a | |
| UA102693C2 (ru) | Производные фенилимидазола как ингибиторы фермента pde10a | |
| TN2012000271A1 (en) | Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors | |
| MY156520A (en) | Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| MX336915B (es) | Derivados de imidazol como inhibidores de la enzima pde10a. | |
| TN2013000200A1 (en) | Imidazole derivatives as pde 10a enzyme inhibitors | |
| TN2014000288A1 (en) | Pde9 inhibitors with imidazo triazinone backbone | |
| CY1116689T1 (el) | Παραγωγα ιμιδαζολης ως αναστολεις του ενζυμου pde10a | |
| MX2019014982A (es) | Derivados de 7h-imidazo[1-5-a]pirazin-8-ona como inhibidores de la fosfodiesterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos. |